Table 2.
Current Clinical Trials Based on Exosomes in Lung Cancer.
| NCT Number | Title | Status | Conditions | Interventions |
|---|---|---|---|---|
| NCT03542253 | Combined Diagnosis of CT and Exosome in Early Lung Cancer | Unknown status | Early Lung Cancer | Procedure: Surgery |
| NCT04529915 | Multicenter Clinical Research for Early Diagnosis of Lung Cancer Using Blood Plasma Derived Exosome | Active, not recruiting | Lung Cancer | Diagnostic Test: Exosome sampling |
| NCT01159288 | Trial of a Vaccination With Tumor Antigen-loaded Dendritic Cell-derived Exosomes | Completed | NSCLC | Biological: Dex2 |
| NCT03830619 | Serum Exosomal Long Noncoding RNAs as Potential Biomarkers for Lung Cancer Diagnosis | Recruiting | Lung Cancer (Diagnosis) | Diagnostic Test: collect samples |
| NCT04629079 | Improving the Early Detection of Lung Cancer by Combining Exosomal Analysis of Hypoxia With Standard of Care Imaging | Recruiting | Lung Cancer | |
| NCT04315753 | Circulating and Imaging Biomarkers to Improve Lung Cancer Management and Early Detection | Recruiting | Lung Cancer | Other: LDCT (Low Dose CT) |
| NCT04427475 | Prediction of Immunotherapeutic Effect of Advanced Non-small Cell Lung Cancer | Recruiting | NSCLC |
Drug: pabolizumab Drug: nafulizumab |
| NCT02869685 | Clinical Research for the Consistency Analysis of PD-L1 in Lung Cancer Tissue and Plasma Exosome Before and After Radiotherapy | Unknown status | NSCLC | Radiation: radiotherapy |
| NCT04323579 | Validation of Multiparametric Models and Circulating and Imaging Biomarkers to Improve Lung Cancer EARLY Detection. | Recruiting | Lung Cancer | |
| NCT03317080 | Dynamic Monitoring Circulating Tumor DNA in Surgical Patients With Lung Cancer | Active, not recruiting | Lung Cancer | |
| NCT02921854 | Detection of Circulating Biomarkers of Immunogenic Cell Death | Completed | NSCLC | Other: Blood withdrawal |
| NCT03108677 | Circulating Exosome RNA in Lung Metastases of Primary High-Grade Osteosarcoma | Recruiting | Lung Metastases Osteosarcoma | Other: Blood samples |
| NCT04182893 | Clinical Study of ctDNA and Exosome Combined Detection to Identify Benign and Malignant Pulmonary Nodules | Recruiting | Pulmonary Nodules | Diagnostic Test: ctDNA and Exosome Combined Detection |
| NCT03228277 | Olmutinib Trial in T790M (+) NSCLC Patients Detected by Liquid Biopsy Using BALF Extracellular Vesicular DNA | Completed | NSCLC | Drug: Olmutinib |
| NCT04499794 | The Study of Exosome EML4-ALK Fusion in NSCLC Clinical Diagnosis and Dynamic Monitoring | Recruiting |
•Untreated Advanced NSCLC •FISH Identified ALK Fusion Positive or Negative |
Drug: ALK inhibitor |
| NCT03236675 | Detection of Either the EML4-ALK Gene Rearrangements or the T790M EGFR Mutation in the Plasma of Advanced NSCLC Patients | Active, not recruiting | Carcinoma, Non- Small-Cell Lung | |
| NCT01629498 | Image-Guided, Intensity-Modulated Photon or Proton Beam Radiation Therapy in Treating Patients With Stage II-IIIB Non-small Cell Lung Cancer | Recruiting |
•Recurrent NSCLC •Stage II NSCLC AJCC v7 •Stage IIA NSCLC AJCCv7 •Stage IIB NSCLC AJCCv7 •Stage IIIA NSCLC AJCC v7 •Stage IIIB NSCLC AJCC v7 |
•Radiation: Image Guided Radiation Therapy •Radiation: Intensity-Modulated Radiation Therapy •Other: Laboratory Biomarker Analysis •Radiation: Photon Beam Radiation Therapy •Radiation: Proton Beam Radiation Therapy •Other: Questionnaire Administration |
| NCT02662621 | Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors | Completed | Cancer |
•Other: blood samples •Other: Urine samples |